Skip to content
★ Sign in to follow
NH

Neil Harris Cohen

Board Director
Director
Chemomab Therapeutics Ltd.
Insider activity · 24 months0 buys2 salesCumulative net flow
Total declarations
9
Company
1
▲ Purchases (6 ops.)
€127k
▼ Sales (3 ops.)
€10k

Latest filing published 01 Sept 2026 for Chemomab Therapeutics Ltd., €2,402.

Filing timeline

BuySale
Neil Harris Cohen

Insider track record

Disclosed buys
6
Disclosed sells
3
T+90 hit rate
33%
T+90 mean return
-21.0%

Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Neil Harris Cohen: trading record in brief

This profile gathers the share dealings of Neil Harris Cohen in Chemomab Therapeutics Ltd., where the filings describe the role as board member. We count 9 filings; the first trade dates from 16 March 2021 and the latest from 28 August 2026.

In open-market terms, that means 6 purchases worth €127k on one side and 3 sales worth €10k on the other. Netting one side against the other leaves €117k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2026 to date brings no purchases and 2 sales.

In size, the median ticket on the buying side is €8,105. 3 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 1 September 2026, the filings show an open-market sale worth €3,187 in Chemomab Therapeutics Ltd. The clock since the last published purchase (19 May 2022) now reads 1,634 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Neil Harris Cohen

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations6 total

6 of 6 declarations